Is the business good?
How good a business is XERS?
Xeris Biopharma Holdings, Inc. earns 23% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
23%
Return on invested capital · cost of capital 9.0% · 14 points above what the capital costs: growth creates value
- Operating margin
- 11%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q1 2026
- Share count, year on year
- +17%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 10%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −415% |
| FY2021 | −232% |
| FY2022 | −74% |
| FY2023 | −27% |
| FY2024 | −17% |
| FY2025 | 8.5% |
Details›
- Gross margin12 months to Q1 2026
- 86%
- Operating margin12 months to Q1 2026
- 11%
- Net margin12 months to Q1 2026
- 3.8%
- R&D as % of revenue
- 10%
- Revenue, trailing twelve months
- $315M
- Net income, trailing twelve months
- $12M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 23%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #12 of 28 by Smart Score